We are international
Donate
publications TEXT SIZE   
   back

Spring 2004 Volume 5, Issue 10:
Treating Multiple Myeloma: The Little Rock Approach
By Bart Barlogie, MD, PhD
Peripheral blood stem cell (PBSC)-supported high-dose melphalan 200 mg/m2 is now considered standard therapy for patients with symptomatic or progressive myeloma. During the last five years, additional new agents effecting salvage rates of 30% - 50%
04.26.04

Be the first to comment

 related articles